Solomon Islands
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.081 (0.042–0.14) 14 (7.5–24)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.8 (0.38–1.4) 142 (67–244)
Incidence  (includes HIV+TB) 0.52 (0.43–0.62) 92 (76–110)
Incidence (HIV+TB only)        
Case detection, all forms (%) 70 (58–84)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4.5 (2.7–6.4) 0 (0–21)
MDR-TB cases among notified pulmonary
TB cases
11 (7–15) 0 (0–3)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 136   5
Pulmonary, clinically diagnosed 105   0
Extrapulmonary 114   0
       
Total new and relapse 360    
Previously treated, excluding relapses 8    
Total cases notified 368    
Among 360 new and relapse cases:
66 (18%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 7 (54%) 7
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 48 (13)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 88
Previously treated cases, excluding relapse, registered in 2012 91
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 1.9
% Funded domestically 5%
% Funded internationally 95%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-20 Data: www.who.int/tb/data